These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

214 related articles for article (PubMed ID: 20043166)

  • 1. Sunitinib in combination with docetaxel in patients with advanced solid tumors: a phase I dose-escalation study.
    Robert F; Sandler A; Schiller JH; Liu G; Harper K; Verkh L; Huang X; Ilagan J; Tye L; Chao R; Traynor AM
    Cancer Chemother Pharmacol; 2010 Sep; 66(4):669-80. PubMed ID: 20043166
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Sunitinib in combination with paclitaxel plus carboplatin in patients with advanced solid tumors: phase I study results.
    Heath EI; Blumenschein GR; Cohen RB; Lorusso PM; Loconte NK; Kim ST; Ruiz-Garcia A; Chao RC; Wilding G
    Cancer Chemother Pharmacol; 2011 Sep; 68(3):703-12. PubMed ID: 21140147
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A phase I dose-escalation and pharmacokinetic study of sunitinib in combination with pemetrexed in patients with advanced solid malignancies, with an expanded cohort in non-small cell lung cancer.
    Chow LQ; Blais N; Jonker DJ; Laurie SA; Diab SG; Canil C; McWilliam M; Thall A; Ruiz-Garcia A; Zhang K; Tye L; Chao RC; Camidge DR
    Cancer Chemother Pharmacol; 2012 Mar; 69(3):709-22. PubMed ID: 21989766
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A Phase I Clinical, Pharmacokinetic, and Pharmacodynamic Study of Weekly or Every Three Week Ixabepilone and Daily Sunitinib in Patients with Advanced Solid Tumors.
    Montero AJ; Kwon D; Flores A; Kovacs K; Trent JC; Benedetto P; Rocha-Lima C; Merchan JR
    Clin Cancer Res; 2016 Jul; 22(13):3209-17. PubMed ID: 26864210
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A phase I study of sunitinib combined with modified FOLFOX6 in patients with advanced solid tumors.
    Leong S; Eckhardt SG; Chan E; Messersmith WA; Spratlin J; Camidge DR; Diab S; Khosravan R; Lin X; Chow Maneval E; Lockhart AC
    Cancer Chemother Pharmacol; 2012 Jul; 70(1):65-74. PubMed ID: 22623210
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A phase I study of sunitinib plus capecitabine in patients with advanced solid tumors.
    Sweeney CJ; Chiorean EG; Verschraegen CF; Lee FC; Jones S; Royce M; Tye L; Liau KF; Bello A; Chao R; Burris HA
    J Clin Oncol; 2010 Oct; 28(29):4513-20. PubMed ID: 20837944
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Phase I study of sunitinib plus S-1 and cisplatin in Japanese patients with advanced or metastatic gastric cancer.
    Boku N; Muro K; Machida N; Hashigaki S; Kimura N; Suzuki M; Lechuga M; Miyata Y
    Invest New Drugs; 2014 Apr; 32(2):261-70. PubMed ID: 23665950
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Phase I study of safety and tolerability of sunitinib in combination with sirolimus in patients with refractory solid malignancies and determination of VEGF (VEGF-A) and soluble VEGF-R2 (sVEGFR2) in plasma.
    Li J; Kluger H; Devine L; Lee JJ; Kelly WK; Rink L; Saif MW
    Cancer Chemother Pharmacol; 2016 Jun; 77(6):1193-200. PubMed ID: 27103123
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical and pharmacokinetic study of sunitinib and docetaxel in women with advanced breast cancer.
    Bergh J; Mariani G; Cardoso F; Liljegren A; Awada A; Viganò L; Huang X; Verkh L; Kern KA; Giorgetti C; Gianni L
    Breast; 2012 Aug; 21(4):507-13. PubMed ID: 22336056
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Sunitinib in combination with gemcitabine for advanced solid tumours: a phase I dose-finding study.
    Michaelson MD; Zhu AX; Ryan DP; McDermott DF; Shapiro GI; Tye L; Chen I; Stephenson P; Patyna S; Ruiz-Garcia A; Schwarzberg AB
    Br J Cancer; 2013 Apr; 108(7):1393-401. PubMed ID: 23511559
    [TBL] [Abstract][Full Text] [Related]  

  • 11. An exploratory study of sunitinib in combination with docetaxel and trastuzumab as first-line therapy for HER2-positive metastatic breast cancer.
    Cardoso F; Canon JL; Amadori D; Aldrighetti D; Machiels JP; Bouko Y; Verkh L; Usari T; Kern KA; Giorgetti C; Dirix L
    Breast; 2012 Dec; 21(6):716-23. PubMed ID: 23022045
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Sunitinib combined with pemetrexed and carboplatin in patients with advanced solid malignancies--results of a phase I dose-escalation study.
    Blais N; Camidge DR; Jonker DJ; Soulières D; Laurie SA; Diab SG; Ruiz-Garcia A; Thall A; Zhang K; Chao RC; Chow LQ
    Invest New Drugs; 2013 Dec; 31(6):1487-98. PubMed ID: 23963796
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A phase I trial of a Bcl-2 antisense (G3139) and weekly docetaxel in patients with advanced breast cancer and other solid tumors.
    Marshall J; Chen H; Yang D; Figueira M; Bouker KB; Ling Y; Lippman M; Frankel SR; Hayes DF
    Ann Oncol; 2004 Aug; 15(8):1274-83. PubMed ID: 15277270
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A phase I/II study of lenalidomide in combination with sunitinib in patients with advanced or metastatic renal cell carcinoma.
    Rini B; Redman B; Garcia JA; Burris HA; Li S; Fandi A; Beck R; Jungnelius U; Infante JR
    Ann Oncol; 2014 Sep; 25(9):1794-1799. PubMed ID: 24914044
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Frequent dose interruptions are required for patients receiving oral kinase inhibitor therapy for advanced renal cell carcinoma.
    La Vine DB; Coleman TA; Davis CH; Carbonell CE; Davis WB
    Am J Clin Oncol; 2010 Jun; 33(3):217-20. PubMed ID: 19745694
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Sunitinib combined with pemetrexed and cisplatin: results of a phase I dose-escalation and pharmacokinetic study in patients with advanced solid malignancies, with an expanded cohort in non-small cell lung cancer and mesothelioma.
    Camidge DR; Blais N; Jonker DJ; Soulières D; Doebele RC; Ruiz-Garcia A; Thall A; Zhang K; Laurie SA; Chao RC; Chow LQ
    Cancer Chemother Pharmacol; 2013 Feb; 71(2):307-19. PubMed ID: 23108697
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A phase I study of liposomal-encapsulated docetaxel (LE-DT) in patients with advanced solid tumor malignancies.
    Deeken JF; Slack R; Weiss GJ; Ramanathan RK; Pishvaian MJ; Hwang J; Lewandowski K; Subramaniam D; He AR; Cotarla I; Rahman A; Marshall JL
    Cancer Chemother Pharmacol; 2013 Mar; 71(3):627-33. PubMed ID: 23274395
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Bortezomib plus docetaxel in advanced non-small cell lung cancer and other solid tumors: a phase I California Cancer Consortium trial.
    Lara PN; Koczywas M; Quinn DI; Lenz HJ; Davies AM; Lau DH; Gumerlock PH; Longmate J; Doroshow JH; Schenkein D; Kashala O; Gandara DR
    J Thorac Oncol; 2006 Feb; 1(2):126-34. PubMed ID: 17409841
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Phase I and pharmacokinetic study of sunitinib in pediatric patients with refractory solid tumors: a children's oncology group study.
    Dubois SG; Shusterman S; Ingle AM; Ahern CH; Reid JM; Wu B; Baruchel S; Glade-Bender J; Ivy P; Grier HE; Adamson PC; Blaney SM
    Clin Cancer Res; 2011 Aug; 17(15):5113-22. PubMed ID: 21690570
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Sunitinib in combination with docetaxel and prednisone in chemotherapy-naive patients with metastatic, castration-resistant prostate cancer: a phase 1/2 clinical trial.
    Zurita AJ; George DJ; Shore ND; Liu G; Wilding G; Hutson TE; Kozloff M; Mathew P; Harmon CS; Wang SL; Chen I; Chow Maneval E; Logothetis CJ
    Ann Oncol; 2012 Mar; 23(3):688-694. PubMed ID: 21821830
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.